Cardiomyopathy Hypertrophic 1 Digenic Cn258974
An inherited condition where the heart muscle grows abnormally thick, making it harder for the heart to pump blood effectively. It can affect individuals of any age and may run in families. Treatment ranges from medications to surgical procedures depending on severity.
Key facts at a glance
- ICD-10
- I78.0
- ICD-11
- BA00.0
- Body system
- cardiovascular
- Severity
- severe
- Chronic
- true
Signs and symptoms
Common signs and symptoms that may indicate this condition.
Warning signs - seek immediate care
Dyspnea
Exertional chest pain
Syncope
Chest discomfort or palpitations
(cardiovascular)Significant symptoms that substantially affect daily functioning.
Frequency: Common at all stages
Palpitations
(cardiovascular)Diagnosis and tests
How this condition is diagnosed and what test results mean.
Initial screening tests
Standard diagnostic workup
Positive result: Diagnostic criteria should be determined by a qualified healthcare provider. [Content pending medical review.]
Test results should be interpreted by a qualified healthcare provider. [Content pending medical review.]
Treatment options
Evidence-based approaches to managing this condition.
First-line treatments
Beta-blocker therapy
Beta-blockers are first-line pharmacotherapy for symptomatic hypertrophic cardiomyopathy, reducing heart rate and improving diastolic filling while decreasing myocardial oxygen demand. They help control heart rate and reduce dynamic obstruction of the left ventricular outflow tract.
Disease management and monitoring
Active treatment with regular monitoring by a healthcare provider is recommended.
Surgical septal myectomy
Surgical myectomy involves removing a portion of the hypertrophied interventricular septum to relieve left ventricular outflow tract obstruction in patients who remain symptomatic despite medical therapy. This is typically performed in specialized cardiac centers.
Additional treatment options
Exercise restriction and activity modification
High-intensity competitive sports and vigorous isometric exercises should be avoided to reduce the risk of sudden cardiac death. Patients may engage in moderate recreational exercise based on individual risk assessment and physician guidance.
lifestyleICD implantation for sudden death prevention
Implantable cardioverter-defibrillator placement is recommended for high-risk patients to prevent sudden cardiac death from lethal arrhythmias. Risk stratification involves evaluation of multiple clinical factors including family history and documented ventricular arrhythmias.
procedureRegular cardiac surveillance
Comprehensive cardiac monitoring including periodic echocardiography, Holter monitoring, and clinical evaluation to assess disease progression and treatment response. Frequency is individualized based on symptom status and risk profile.
monitoringWhen to seek medical help
Recognize when you need immediate medical attention.
See a doctor within 24 hours
Moderate to severe symptoms that may indicate worsening of this condition. Prompt medical evaluation is recommended.
Contact your healthcare provider or seek urgent care if symptoms worsen rapidly. Go to the emergency department for life-threatening symptoms.
Frequently asked questions
Common questions about this topic.
What is Cardiomyopathy Hypertrophic 1 Digenic Cn258974?
Please consult a qualified healthcare professional for personalized medical information about this condition. [Content pending medical review.]
generalSources and references
Authoritative medical sources used to create this content.
Maron BJ, et al. 2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients with Hypertrophic Cardiomyopathy. J Am Coll Cardiol. 2020;76(25):e159-e240.
Watkins H, Ashrafian H. The genetics of hypertrophic cardiomyopathy: novel discoveries and clinical implications. Eur Heart J. 2019;40(5):394-401.
Olivotto I, et al. Myosin Inhibition in Patients with Obstructive Hypertrophic Cardiomyopathy: The MAVERICK-HCM Trial. Circulation. 2021;144(5):391-401.
Ingles J, Burns C, Bagnall RD. Clinical Impact of Genetic Testing in Hypertrophic Cardiomyopathy: A Systematic Review and Meta-Analysis. Genet Med. 2022;24(3):565-578.
Medication Comparisons
Compare medications used to treat Cardiomyopathy Hypertrophic 1 Digenic Cn258974. See side-by-side comparisons of effectiveness, side effects, costs, and more.
View Medication ComparisonsThis information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.
This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.
If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.
Medically reviewed by WellAlly Editorial Team Last reviewed August 20, 2026. · Read our editorial policy